4 not yet recruiting, 3 unknown, 2 recruiting, 1 active not recruiting. 8 Phase 2, 4 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Unknown 3, Not yet recruiting 2, Active not recruiting 1, Completed 1, Recruiting 1 |
| Phase 3 | 4 | Unknown 3, Not yet recruiting 1 |
| Phase 1 | 3 | Not yet recruiting 2, Recruiting 1 |
Follow Fludarabine (FLU): new trials by email Literature Review of Fludarabine (FLU) trials Research Report on Fludarabine (FLU)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory Leukemia CD7 CAR-γδT cell（QH106）, Fludarabine (FLU), Cyclophosphamide (CTX) - Leukemia | Phase 1 | Not yet recruiting | Anhui Provincial Hospital | 9 | 2025-08-18 | 2025-08-13 |
| QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS) Allogeneic TCR-enhanced γδ T cell(QH101), Fludarabine (FLU), Cyclophosphamide (CTX) - MDS, AML | Phase 1 | Not yet recruiting | Anhui Provincial Hospital | 9 | 2025-08-15 | 2025-08-20 |
| Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic Anemia Total Marrow Irradiation, Fludarabine (FLU), Melphalan (Mel) - Aplastic Anemia Idiopathic | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 11 | 2025-07-20 | 2025-07-22 |
| VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT Venetoclax (VEN), Decitabine (DAC), Busulfan (Bu) - Older Patients, Myeloid Malignancies | Phase 2 / Phase 3 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 160 | 2025-07-15 | 2025-07-04 |
| A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors NK042, Fludarabine (FLU), Cyclophosphamide (CTX) - Advanced Solid Tumors | Phase 1 | Recruiting | Shanghai NK Cell Technology Co., LTD | 76 | 2025-02-07 | 2026-04-06 |
| G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan (BU) - Secondary Acute Myeloid Leukemia Evolving From MDS, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 232 | 2022-07-01 | 2022-07-08 |
| G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan - Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 242 | 2022-07-01 | 2023-03-21 |
| G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT Granulocyte Colony-Stimulating Factor(G-CSF), Decitabine (DAC), Busulfan (BU) - Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 242 | 2021-01-15 | 2021-01-19 |
| Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Fludarabine (FLU), Cyclophosphamide (CY), Total Body Irradiation (TBI) - Acute Myeloid Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Active not recruiting | Masonic Cancer Center, University of Minnesota | 22 | 2019-01-02 | 2026-01-06 |
| Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders Total Body Irradiation (TBI) (Plan 1), Cyclophosphamide (CY) (Plan 1), Fludarabine (FLU) - Fanconi Anemia, Severe Aplastic Anemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 48 | 2018-11-13 | 2026-01-30 |
| Bone Marrow Transplantation in Young Adults With Severe Sickle Cell Disease Conditioning Regimen with Bone Marrow Transplant - Sickle Cell Disease | Phase 2 | Completed | Emory University | 22 | 2012-03-01 | 2017-11-21 |
Myelodysplastic Syndromes (3) · Anemia, Aplastic (2) · Anemia (1) · Anemia, Refractory, with Excess of Blasts (1) · Anemia, Sickle Cell (1) · Bone Marrow Failure Disorders (1) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Dyskeratosis Congenita (1) · Fanconi Anemia (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1) · Hemolysis (1) · Hodgkin Disease (1) · Leukemia (1)
Nanfang Hospital, Southern Medical University (4) · Anhui Provincial Hospital (2) · Masonic Cancer Center, University of Minnesota (2) · Emory University (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Shanghai NK Cell Technology Co., LTD (1)
China (5) · United States (3)
Qifa Liu (3) · Lakshmanan Krishnamurti, MD (1) · Margaret MacMillan, MD, Msc, FRCPC (1) · Zimin Sun (1)
R34HL108761 (1)